Works matching AU Gantz, Ira


Results: 51
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine.

    Published in:
    Obesity (19307381), 2007, v. 15, n. 8, p. 2027, doi. 10.1038/oby.2007.242
    By:
    • Erondu, Ngozi;
    • Addy, Carol;
    • Kaifeng Lu;
    • Mallick, Madhuja;
    • Musser, Bret;
    • Gantz, Ira;
    • Proietto, Joseph;
    • Astrup, Arne;
    • Toubro, Søren;
    • Rissannen, Aila M.;
    • Tonstad, Serena;
    • Haynes, William G.;
    • Gottesdiener, Keith M.;
    • Kaufman, Keith D.;
    • Amatruda, John M.;
    • Heymsfield, Steven B.
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42

    1197-P: Two-Year Effects of Ertugliflozin on Renal Function.

    Published in:
    Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1197-P
    By:
    • CHERNEY, DAVID;
    • HEERSPINK, HIDDO L.;
    • FREDERICH, ROBERT;
    • MALDONADO, MARIO;
    • PONG, ANNPEY;
    • XU, ZHI JIN;
    • LIU, JIE;
    • MANCUSO, JAMES P.;
    • GANTZ, IRA;
    • TERRA, STEVEN G.
    Publication type:
    Article
    43
    44
    45
    46
    47

    A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.

    Published in:
    BMC Endocrine Disorders, 2017, v. 17, p. 1, doi. 10.1186/s12902-017-0219-x
    By:
    • Seung-Hwan Lee;
    • Gantz, Ira;
    • Round, Elizabeth;
    • Latham, Melanie;
    • O'Neill, Edward A.;
    • Ceesay, Paulette;
    • Suryawanshi, Shailaja;
    • Kaufman, Keith D.;
    • Engel, Samuel S.;
    • Eseng Lai
    Publication type:
    Article
    48

    Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.

    Published in:
    European Journal of Heart Failure, 2025, v. 27, n. 3, p. 521, doi. 10.1002/ejhf.3511
    By:
    • Pandey, Ambarish;
    • Kolkailah, Ahmed A.;
    • McGuire, Darren K.;
    • Frederich, Robert C.;
    • Cater, Nilo B.;
    • Cosentino, Francesco;
    • Pratley, Richard E.;
    • Dagogo‐Jack, Samuel;
    • Cherney, David Z.I.;
    • Wynant, Willy;
    • Gantz, Ira;
    • Mancuso, James P.;
    • Masiukiewicz, Urszula;
    • Cannon, Christopher P.
    Publication type:
    Article
    49

    Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

    Published in:
    Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 781, doi. 10.1111/dom.13574
    By:
    • Roussel, Ronan;
    • Duran‐García, Santiago;
    • Zhang, Yilong;
    • Shah, Suneri;
    • Darmiento, Carolyn;
    • Shankar, R. Ravi;
    • Golm, Gregory T.;
    • Lam, Raymond L. H.;
    • O'Neill, Edward A.;
    • Gantz, Ira;
    • Kaufman, Keith D.;
    • Engel, Samuel S.
    Publication type:
    Article
    50